Isotretinoin (Accutane) and serious psychiatric adverse events

被引:11
|
作者
O'Connell, KA [1 ]
Wilkin, JK
Pitts, M
机构
[1] US FDA, Ctr Drug Evaluat & Res, Div Dermatol & Dental Drug Products, Rockville, MD 20857 USA
[2] US FDA, Ctr Drug Evaluat & Res, Off Drug Safety, Rockville, MD 20857 USA
关键词
D O I
10.1067/mjd.2002.12
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
引用
收藏
页码:306 / 308
页数:3
相关论文
共 50 条
  • [31] Commentary: Are serious adverse events inevitable?
    Manji, Rizwan A.
    Arora, Rakesh C.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2021, 162 (06): : 1779 - 1780
  • [35] Psychiatric Adverse Events in Patients Taking Isotretinoin as Reported in a Food and Drug Administration Database From 1997 to 2017
    Singer, Sean
    Tkachenko, Elizabeth
    Sharma, Priyank
    Barbieri, John S.
    Mostaghimi, Arash
    JAMA DERMATOLOGY, 2019, 155 (10) : 1162 - 1166
  • [36] TRANSIENT ACUTE MYOPIA RESULTING FROM ISOTRETINOIN (ACCUTANE) THERAPY
    PALESTINE, AG
    ANNALS OF OPHTHALMOLOGY, 1984, 16 (07): : 660 - &
  • [37] Rates of adverse and serious adverse events in children with cystic fibrosis
    Pittman, Jessica E.
    Khan, Umer
    Laguna, Theresa A.
    Heltshe, Sonya
    Goss, Christopher H.
    Sanders, Don B.
    JOURNAL OF CYSTIC FIBROSIS, 2021, 20 (06) : 972 - 977
  • [38] Price Responsiveness to Psychiatric and Medical Drugs and Adverse Clinical Events among Patients with Serious Mental Illness
    Fung, Vicki
    Price, Mary
    Hsu, John
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2017, 20 : S10 - S11
  • [39] Limited additional serious adverse events associated with concomitant immunomodulatory treatment in people with atypical psychiatric disease
    Fani-Molky, Parisa
    Jiang, Jocelyn
    Naz, Sabrina
    Brown, David
    Harris, Anthony
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2024, 58 (11): : 1001 - 1007
  • [40] Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
    Zhao, Bin
    Zhao, Hong
    Zhao, Jiaxin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6